Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Patients with malignant Perivascular epithelioid cell tumor were treated with nab-sirolimus 100 mg/m 2 intravenously once weekly for 2 weeks in 3-week cycles
Primary outcome measures:
Objective response rate (ORR)
The authors' conclusion was nab-Sirolimus is active in patients with malignant Perivascular epithelioid cell tumor. The response rate, durability of response, disease control rate, and safety profile support that nab-sirolimus represents an important new treatment option for this disease
Wagner et al. 2021 Journal of Clinical Oncology 39(33): 3660-3670
…